Can the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development?

Abstract

Future VirologyVol. 9, No. 5 EditorialCan the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development?Angela Corona, Francesca Esposito & Enzo TramontanoAngela Corona Dept. of Life & Environmental Sciences, University of Cagliari, Cittadella di Monserrato SS554, 09042, Monserrato (Cagliari), ItalySearch for more papers by this author, Francesca Esposito Dept. of Life & Environmental Sciences, University of Cagliari, Cittadella di Monserrato SS554, 09042, Monserrato (Cagliari), ItalySearch for more papers by this author & Enzo Tramontano Dept. of Life & Environmental Sciences, University of Cagliari, Cittadella di Monserrato SS554, 09042, Monserrato (Cagliari), ItalySearch for more papers by this authorPublished Online:16 Jun 2014https://doi.org/10.2217/fvl.14.24AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: dual inhibitorsHIVRNase Hsmall-molecule inhibitors References1 Esposito F, Corona A, Tramontano E. HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions. Mol. Biol. Int. 2012, 586401 (2012).Crossref, Medline, Google Scholar2 Schatz O, Cromme FV, Grüninger-Leitch F, Le Grice SFJ. Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett. 257(2), 311–314 (1989).Crossref, Medline, CAS, Google Scholar3 Schatz O, Mous J, Le Grice SFJ. HIV-1 RT-associated ribonuclease H displays both endonuclease and 3′–5′ exonuclease activity. EMBO J. 9(4), 1171–1176 (1990).Crossref, Medline, CAS, Google Scholar4 Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 53(2), 521–538 (2010).Crossref, Medline, CAS, Google Scholar5 Cerritelli SM, Frolova EG, Feng C, Grinberg A, Love PE, Crouch RJ. Failure to produce mitochondrial DNA results in embryonic lethality in rnaseh1 null mice. Mol. Cell. 11, 807–815 (2003).Crossref, Medline, CAS, Google Scholar6 Corona A, Masaoka T. Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase. Future Med. Chem. 5(18), 2127–2139 (2013).Crossref, Medline, CAS, Google Scholar7 Himmel DM, Maegley KA, Pauly TA et al. Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 17(12), 1625–1635 (2009).Crossref, Medline, CAS, Google Scholar8 Shaw-Reid CA, Munshi V, Graham P et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278(5), 2777–2780 (2003).Crossref, Medline, CAS, Google Scholar9 Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 65(2), 117–124 (2005).Crossref, Medline, CAS, Google Scholar10 Tramontano E, Di Santo R. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr. Med. Chem. 17(26), 2837–2853 (2010).Crossref, Medline, CAS, Google Scholar11 Esposito F, Tramontano E. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors. Antivir. Chem. Chemother. 23(4), 129–144 (2014).Crossref, Medline, Google Scholar12 Kirschberg TA, Balakrishnan M, Squires NH et al. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J. Med. Chem. 52(19), 5781–5784 (2009).Crossref, Medline, CAS, Google Scholar13 Lansdon EB, Liu Q, Leavitt S a et al. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob. Agents Chemother. 55(6), 2905–2915 (2011).Crossref, Medline, CAS, Google Scholar14 Di Grandi M, Olson M, Prashad AS et al. Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg. Med. Chem. Lett. 20(1), 398–402 (2010).Crossref, Medline, CAS, Google Scholar15 Williams PD, Staas DD, Venkatraman S et al. Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg. Med. Chem. Lett. 20(22), 6754–6757 (2010).Crossref, Medline, CAS, Google Scholar16 Rausch JW. Ribonuclease H inhibitors: structural and molecular biology. In: Human Immunodeficiency Virus Reverse Transcriptase A Bench-to-Beside Success. Le Grice SFJ, Gotte M (Eds). Springer, NY, USA, 143–172 (2013).Crossref, Google Scholar17 Chung S, Himmel DM, Jiang J-K et al. Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. J. Med. Chem. 54(13), 4462–4473 (2011).Crossref, Medline, CAS, Google Scholar18 Su H-P, Yan Y, Prasad GS et al. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J. Virol. 84(15), 7625–7633 (2010).Crossref, Medline, CAS, Google Scholar19 Klumpp K, Mirzadegan T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Des. 12(15), 1909–1922 (2006).Crossref, Medline, CAS, Google Scholar20 Himmel DM, Sarafianos SG, Dharmasena S et al. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol. 1(11), 702–712 (2006).Crossref, Medline, CAS, Google Scholar21 Esposito F, Kharlamova T, Distinto S et al. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J. 278(9), 1444–1457 (2011).Crossref, Medline, CAS, Google Scholar22 Distinto S, Esposito F, Kirchmair J et al. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. Eur. J. Med. Chem. 50, 216–229 (2012).Crossref, Medline, CAS, Google Scholar23 Christen MT, Menon L, Myshakina NS, Ahn J, Parniak MA, Ishima R. Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem. Biol. Drug Des. 80(5), 706–716 (2012).Crossref, Medline, CAS, Google Scholar24 Distinto S, Maccioni E, Meleddu R, Corona A, Alcaro S. Molecular aspects of the RT/drug interactions. perspective of dual inhibitors. Curr. Pharm. Des. 19(10), 1850–1859 (2013).Crossref, Medline, CAS, Google Scholar25 Costi R, Me M, Esposito F et al. 6-(1-benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach. J. Med. Chem. 56(i), 8588–8598 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByIn Vitro Anti-HIV-1 Reverse Transcriptase and Integrase Properties of Punica granatum L. Leaves, Bark, and Peel Extracts and Their Main Compounds7 October 2021 | Plants, Vol. 10, No. 10Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase9 June 2021 | Journal of Medicinal Chemistry, Vol. 64, No. 12Targeting HIV-1 RNase H: N’-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants6 July 2020 | Viruses, Vol. 12, No. 7Pyrrolyl Pyrazoles as Non-Diketo Acid Inhibitors of the HIV-1 Ribonuclease H Function of Reverse Transcriptase5 March 2020 | ACS Medicinal Chemistry Letters, Vol. 11, No. 52-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication15 March 2020 | Molecules, Vol. 25, No. 6Scaffold hopping and optimisation of 3’,4’-dihydroxyphenyl- containing thienopyrimidinones: synthesis of quinazolinone derivatives as novel allosteric inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H3 November 2020 | Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 35, No. 1Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developmentsEuropean Journal of Medicinal Chemistry, Vol. 179Prenylated phloroglucinols from Hypericum scruglii, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication30 March 2018 | PLOS ONE, Vol. 13, No. 3Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies1 January 2018 | MedChemComm, Vol. 9, No. 3Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions10 July 2017 | Pathogens and Disease, Vol. 75, No. 6Natural product-inspired esters and amides of ferulic and caffeic acid as dual inhibitors of HIV-1 reverse transcriptaseEuropean Journal of Medicinal Chemistry, Vol. 130Chelation Motifs Affecting Metal-dependent Viral Enzymes: N′-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain20 March 2017 | Frontiers in Microbiology, Vol. 8New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase HAntiviral Research, Vol. 134Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors16 March 2016 | ChemMedChem, Vol. 11, No. 16Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC622 January 2016 | PLOS ONE, Vol. 11, No. 1(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptaseEuropean Journal of Medicinal Chemistry, Vol. 93 Vol. 9, No. 5 Follow us on social media for the latest updates Metrics Downloaded 30 times History Published online 16 June 2014 Published in print May 2014 Information© Future Medicine LtdKeywordsdual inhibitorsHIVRNase Hsmall-molecule inhibitors Financial & competing interests disclosureThe authors acknowledge financial support by Italian Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2010, 2010W2KM5L_003) and Regione Autonoma della Sardegna (RAS grant LR 7/2007 CRP-24915). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download